文献速递临床免疫

线性免疫印迹法检测Mi-2抗体的性能评估:单中心研究

Assessment of a Line Immunoassay for the Detection of Mi-2 Antibodies: Results From a Single Academic Center Investigation.
PubMed 文献 · Am J Clin Pathol · 2022-01-01

该研究在432例连续患者标本中,用线性免疫印迹法(LIA)和免疫沉淀法(IP)平行检测Mi-2抗体,并结合临床诊断回顾分析。结论认为Mi-2免疫检测对DM的符合率不一,需进一步验证。

要点

  • IP法检测Mi-2对皮肌炎总符合率为95.0%,优于LIA法。
  • LIA Mi-2β阳性与non-DM诊断显著相关,特异性存疑。
  • Mi-2免疫检测用于常规评估前需更多验证研究。

核心结论

  • 不同Mi-2抗体检测方法对皮肌炎诊断的符合率存在差异。
  • LIA检测Mi-2β抗体阳性与non-DM诊断显著相关。
  • 需进一步研究验证Mi-2免疫检测在常规患者评估中的价值。

研究设计与样本

  • 单中心研究,连续纳入432例患者标本。
  • 所有标本平行用LIA检测Mi-2α和Mi-2β、IP法检测Mi-2、间接免疫荧光法检测抗核抗体。
  • 对任一Mi-2检测阳性的患者进行回顾性病历复习以确定临床诊断。

主要发现

  • 阳性频率:LIA Mi-2β最高(75.0%),IP法Mi-2为35.0%,LIA Mi-2α为20.0%。
  • IP法Mi-2对DM的总符合率为95.0%,LIA Mi-2α为70.0%,LIA Mi-2β为25.0%。
  • LIA Mi-2β抗体阳性与non-DM诊断显著相关。

关键数值与推荐

  • IP法Mi-2对DM总符合率95.0%。
  • LIA Mi-2α对DM总符合率70.0%。
  • LIA Mi-2β对DM总符合率25.0%。

临床怎么用

  • IP法检测Mi-2对皮肌炎诊断符合率较高,可作为参考方法。
  • LIA Mi-2β阳性需警惕non-DM诊断,不宜单独用于确诊。
  • Mi-2免疫检测用于常规评估前应结合临床并进一步验证。

局限性

  • 单中心研究,结果外推需谨慎。
  • 仅对Mi-2检测阳性患者进行病历回顾,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the performance characteristics of a line immunoassay (LIA) for the detection of Mi-2 antibodies associated with dermatomyositis (DM). METHODS: In total, 432 consecutive patient specimens were tested for Mi-2 antibodies concurrently by LIA (Mi-2α or Mi-2β) or immunoprecipitation (IP) test and antinuclear antibody by indirect immunofluorescence assay using HEp-2 substrate. Following antibody evaluation, results for patients positive in any of the assays for Mi-2 antibody had a retrospective chart review for diagnostic categorization. The performance of all tests was evaluated based on the extracted clinical data. RESULTS: Forty patients were positive in at least one of the Mi-2 assays. The frequency of Mi-2β antibody by LIA was highest (75.0%), followed by Mi-2 by IP (35.0%) and Mi-2α by LIA (20.0%), respectively. Mi-2 by IP had the best total percent agreement for DM (95.0%) compared with 70.0% and 25.0% for the LIA Mi-2α and Mi-2β, respectively. Positivity of the Mi-2β antibody was significantly associated with non-DM diagnosis. CONCLUSIONS: Agreement for DM with assays for detecting Mi-2 is variable. Additional studies are required to validate Mi-2 immunoassays for routine patient evaluation.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Skemp-Dymond G, Lebiedz-Odrobina D, Zuromski LM, et al. Assessment of a Line Immunoassay for the Detection of Mi-2 Antibodies: Results From a Single Academic Center Investigation. Am J Clin Pathol. 2022. PMID: 34661646. doi:10.1093/ajcp/aqab150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。